FK866 (APO866): Precision NAMPT Inhibitor for Cancer Metabolism Research

Executive Summary: FK866 (APO866) is a highly specific, non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), a critical enzyme in the NAD biosynthesis pathway (APExBIO). It displays potent inhibitory activity with a Ki of 0.4 nM and IC50 values from 0.09 nM to 27.2 nM under cell-free and cell-based conditions. FK866 induces selective, caspase-independent cytotoxicity in acute myeloid leukemia (AML) cells via mitochondrial membrane depolarization, while sparing normal hematopoietic progenitors (Ji et al., 2025). In vivo, FK866 halts tumor growth and improves survival in mouse AML and lymphoblastic lymphoma xenograft models. As a research-grade reagent, FK866 is supplied by APExBIO with validated solubility and storage guidelines, enabling robust integration into cancer metabolism and vascular aging workflows.

Biological Rationale

Nicotinamide adenine dinucleotide (NAD) is a central metabolic cofactor required for redox reactions, energy metabolism, and DNA repair. The enzyme NAMPT catalyzes the rate-limiting step in the NAD salvage pathway, making it a validated target for cancer metabolism research (Ji et al., 2025). Malignant cells, particularly in hematologic cancers such as AML, are highly dependent on NAD biosynthesis to sustain proliferation and resist cell death. Targeted inhibition of NAMPT depletes intracellular NAD and ATP, triggering metabolic catastrophe and cell death in cancerous but not normal cells (see our expanded analysis). This selectivity underpins the rationale for using FK866 (APO866) as a precision tool in cancer metabolism and vascular biology research.

Mechanism of Action of FK866 (APO866)

FK866 acts as a highly specific, non-competitive NAMPT inhibitor, binding to an allosteric site and blocking the enzyme's catalytic function. This leads to rapid and sustained depletion of NAD within treated cells. Downstream effects include diminished ATP production, impaired DNA repair, and induction of cell death via a caspase-independent, mitochondrial depolarization mechanism (Ji et al., 2025). Notably, FK866-induced cytotoxicity in AML and other hematologic cancer cells occurs without activating classic apoptotic pathways, distinguishing it from genotoxic or pro-apoptotic agents. FK866 also prompts autophagy, contingent on de novo protein synthesis, further contributing to its anti-cancer efficacy. In non-malignant human hematopoietic progenitors, FK866 exhibits limited cytotoxicity, supporting its selective action (see product overview).

Evidence & Benchmarks

• FK866 inhibits NAMPT activity with a Ki of 0.4 nM and IC50 ranging from 0.09 nM (cell-free) to 27.2 nM (cell-based) (APExBIO).
• In AML cell lines, FK866 depletes intracellular NAD and ATP within 24–48 hours, leading to selective cytotoxicity (Ji et al., 2025).
• FK866 induces cell death independent of caspases, instead causing mitochondrial membrane depolarization and autophagy (Ji et al., 2025).
• In vivo, FK866 prevents tumor growth and enhances survival in xenograft mouse models of AML and lymphoblastic lymphoma (Ji et al., 2025).
• FK866 shows minimal cytotoxicity in normal human hematopoietic progenitor cells at concentrations cytotoxic to cancer cells (see workflow guide).
• NAMPT inhibition by FK866 blocks the beneficial effects of NAD-boosting interventions in vascular smooth muscle cells, underscoring its pathway specificity (Ji et al., 2025).

This article extends prior coverage by providing quantitative potency benchmarks, clarifying selectivity mechanisms, and updating in vivo efficacy data compared to recent thought-leadership on NAMPT inhibition.

Applications, Limits & Misconceptions

FK866 (APO866) is widely used for:

• Dissecting NAD biosynthesis and salvage pathway dependencies in cancer metabolism research.
• Inducing selective cytotoxicity in hematologic malignancy models, especially AML.
• Studying caspase-independent, mitochondrial-driven cell death and autophagy in cancer cells.
• Modeling metabolic vulnerabilities in vascular aging and senescence paradigms (see workflow guide).

However, FK866 is not a pan-cytotoxic agent. Its efficacy is contingent on cellular NAD dependence and salvage pathway activity. Effects in solid tumors, non-hematologic tissues, or in the context of high exogenous NAD precursors may be attenuated. FK866 is intended for research use only and is not approved for clinical application.

Common Pitfalls or Misconceptions

• Not universal: FK866 is not effective in all cancer cell types; those with alternate NAD biosynthesis routes may resist its effects.
• No direct PARP inhibition: FK866 inhibits NAMPT, not PARP enzymes directly; observed PARP modulation is secondary to NAD depletion.
• Solubility constraints: FK866 is insoluble in water; improper solvent use (e.g., aqueous buffers) can compromise experimental consistency.
• Temperature sensitivity: Stock solutions must be stored below -20°C and are recommended for short-term use only.
• Not for clinical use: FK866 is strictly for research applications and has not been approved as a therapeutic agent.

Workflow Integration & Parameters

FK866 (APO866, A4381) is supplied as a solid compound by APExBIO. It is insoluble in water, but soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL). For cell culture or biochemical assays, prepare concentrated stock solutions in DMSO, aliquot, and store at -20°C for several months. Working solutions should be freshly diluted into appropriate media before use. In vitro, effective concentrations typically range from 0.1 nM to 100 nM, depending on cell type and endpoint. In vivo, dosing regimens should be referenced from validated xenograft studies (Ji et al., 2025). Detailed workflow protocols for hematologic cancer and vascular aging models are available in extended guides (workflow integration).

Conclusion & Outlook

FK866 (APO866) remains a gold-standard, non-competitive NAMPT inhibitor for dissecting cancer metabolism and NAD-dependent processes in preclinical research. Its selectivity, potency, and pathway specificity make it indispensable for studies in AML, other hematologic malignancies, and vascular aging. With validated benchmarks and robust supply from APExBIO, FK866 enables reproducible, high-impact research into metabolic vulnerabilities and cell death mechanisms. Future investigations may explore combination strategies, resistance pathways, and translational applications beyond current research limits (product details).